Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
